Use of tenecteplase in the management of acute ischemic stroke: Is it really safe and beneficial compared to other therapies?

Authors

DOI:

https://doi.org/10.31157/an.v28i3.468

Keywords:

Tenecteplasa, ictus, trombolisis, Seguridad, eficacia

References

Pan American Health Organization. Burden of Neurological Conditions [Internet]. [Consulted 22 Mar 2023]. Available in: https://www.paho.org/en/enlace/burden-neurological-conditions

Lozada-Martínez I, Maiguel-Lapeira J, Torres-Llinás D, Moscote-Salazar L, Rahman MM, Pacheco-Hernández A. Letter: Need and Impact of the Development of Robotic Neurosurgery in Latin America. Neurosurgery. 2021; 88(6):E580-E581. doi: 10.1093/neuros/nyab088 DOI: https://doi.org/10.1093/neuros/nyab088

Vaishnav AG. Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke? Ann Indian Acad Neurol. 2022; 25(5):794-795. doi: 10.4103/aian.aian_668_22 DOI: https://doi.org/10.4103/aian.aian_668_22

Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023; 401(10377):645-654. doi: 10.1016/S0140-6736(22)02600-9 DOI: https://doi.org/10.1016/S0140-6736(22)02600-9

Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022; 21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7 DOI: https://doi.org/10.1016/S1474-4422(22)00124-7

Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, Engelter ST, Indredavik B, et al. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2023; 22(2):117-126. doi: 10.1016/S1474-4422(22)00484-7 DOI: https://doi.org/10.1016/S1474-4422(22)00484-7

Kobeissi H, Ghozy S, Turfe B, Bilgin C, Kadirvel R, Kallmes DF, et al. Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials. Front Neurol. 2023; 14:1102463. doi: 10.3389/fneur.2023.1102463 DOI: https://doi.org/10.3389/fneur.2023.1102463

Bonifacio-Delgadillo DM, Castellanos-Pedroza E, Martínez-Guerra BA, Sánchez-Martínez CM, Marquez-Romero JM. Delivering acute stroke care in a middle-income country. The Mexican model: "ResISSSTE Cerebro". Front Neurol. 2023; 14:1103066. doi: 10.3389/fneur.2023.1103066 DOI: https://doi.org/10.3389/fneur.2023.1103066

Cano-Nigenda V, Castellanos-Pedroza E, Manrique-Otero D, Méndez B, Menéndez-Manjarrez MF, Toledo-Treviño R, et al. Barriers to Optimal Acute Management of Stroke: Perspective of a Stroke Center in Mexico City. Front Neurol. 2021; 12:690946. doi: 10.3389/fneur.2021.690946 DOI: https://doi.org/10.3389/fneur.2021.690946

Published

2023-04-24

How to Cite

Brett Cano, P. J., Cano Carmona, A. D., Guevara Lizarazo, G. A., Meza Fandiño, D. F., & Ortega-Sierra, M. (2023). Use of tenecteplase in the management of acute ischemic stroke: Is it really safe and beneficial compared to other therapies?. Archivos De Neurociencias, 28(3). https://doi.org/10.31157/an.v28i3.468

Issue

Section

Letter to Editor

Most read articles by the same author(s)